Free Submission Public Relations &
Deutsch English

TAKEDA, Vortioxetine (Brintellix) - US Approval for MDD Likely in October

TAKEDA, Vortioxetine (Brintellix) - US Approval for MDD Likely in October - new market research report published

Print article Print article
2014-01-28 14:21:01 - TAKEDA, Vortioxetine (Brintellix) - US Approval for MDD Likely in October - a new market research report on

Takeda´s late stage pipeline candidate - Vortioxetine (Filed, Partnered with Lundbeck, US PDUFA on October 2nd) is expected to get FDA approval for the treatment of Major Depressive Disorder (MDD). Despite the fact that antidepressant market will be ~fully genericized by 2013 (when Cymbalta will go off patent in Dec 2013), there are ~dozen of compounds in mid-late stage development for the treatment of MDD (Table-1).

Increasing prevalence, high unmet need (poor tolerability, moderate efficacy, and thus switching as an unavoidable phenomenon among existing options), and treatment resistance create the need for newer options and still present an attractive market for new entrants. Reported PhIII data of Vortioxetine look. However, other pipeline candidates are chasing Vortioxetine very closely.



PhIII data from

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact